ArticleVaccines2022
High Efficiency of Low Dose Preparations of an Inactivated Lumpy Skin Disease Virus Vaccine Candidate.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Evaluation of an interferon-gamma release assay for early detection of lumpy skin disease virus infection and vaccination in cattle.Microbiology spectrum · 2025Article
- Review
- The Safety and Efficacy of New DIVA Inactivated Vaccines Against Lumpy Skin Disease in Calves.Vaccines · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Capripox virus-induced diseases are commonly described as the most serious poxvirus diseases of production animals, as they have a significant impact on national and global economies. Therefore, they are classified as notifiable diseases under the guidelines of the World Organization for Animal Health (OIE). Controlling lumpy skin disease viral infections is based on early detection, slaughter of affected herds, and ring vaccinations. Until now, only live attenuated vaccines have been commercially available, which often induce adverse effects in vaccinated animals. Furthermore, their application leads to the loss of the "disease-free" status of the respective country. For these reasons, inactivated vaccines have increasingly generated interest. Since 2016, experimental studies have been published showing the high efficacy of inactivated capripox virus vaccines. In the present study, we examined the minimum protective dose of a BEI-inactivated LSDV-Serbia field strain adjuvanted with a low-molecular-weight copolymer adjuvant. Unexpectedly, even the lowest dose tested, with a virus titer of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.